Logo image of IKT

INHIBIKASE THERAPEUTICS INC (IKT) Stock Fundamental Analysis

NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD

2.25  +0.01 (+0.45%)

Fundamental Rating

3

Overall IKT gets a fundamental rating of 3 out of 10. We evaluated IKT against 567 industry peers in the Biotechnology industry. While IKT has a great health rating, there are worries on its profitability. IKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IKT has reported negative net income.
In the past year IKT has reported a negative cash flow from operations.
In the past 5 years IKT always reported negative net income.
In the past 5 years IKT always reported negative operating cash flow.
IKT Yearly Net Income VS EBIT VS OCF VS FCFIKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of IKT (-27.91%) is better than 69.43% of its industry peers.
IKT's Return On Equity of -29.01% is fine compared to the rest of the industry. IKT outperforms 78.62% of its industry peers.
Industry RankSector Rank
ROA -27.91%
ROE -29.01%
ROIC N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
IKT Yearly ROA, ROE, ROICIKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

IKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IKT Yearly Profit, Operating, Gross MarginsIKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IKT has been increased compared to 1 year ago.
IKT has more shares outstanding than it did 5 years ago.
IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IKT Yearly Shares OutstandingIKT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IKT Yearly Total Debt VS Total AssetsIKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 25.62 indicates that IKT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 25.62, IKT belongs to the best of the industry, outperforming 95.58% of the companies in the same industry.
IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.62
ROIC/WACCN/A
WACC10.04%
IKT Yearly LT Debt VS Equity VS FCFIKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 26.37 indicates that IKT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 26.37, IKT belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
A Quick Ratio of 26.37 indicates that IKT has no problem at all paying its short term obligations.
IKT has a Quick ratio of 26.37. This is amongst the best in the industry. IKT outperforms 97.70% of its industry peers.
Industry RankSector Rank
Current Ratio 26.37
Quick Ratio 26.37
IKT Yearly Current Assets VS Current LiabilitesIKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.85%, which is quite impressive.
Looking at the last year, IKT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)28.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.01% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.11%
EPS Next 2Y33.42%
EPS Next 3Y21.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IKT Yearly Revenue VS EstimatesIKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M
IKT Yearly EPS VS EstimatesIKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IKT Price Earnings VS Forward Price EarningsIKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IKT Per share dataIKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as IKT's earnings are expected to grow with 21.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.42%
EPS Next 3Y21.01%

More info and screens

0

5. Dividend

5.1 Amount

IKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (5/2/2025, 8:02:10 PM)

2.25

+0.01 (+0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-13 2025-05-13
Inst Owners66.63%
Inst Owner Change0%
Ins Owners4.27%
Ins Owner Change0%
Market Cap167.26M
Analysts80
Price Target8.16 (262.67%)
Short Float %2.38%
Short Ratio9.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-272.56%
Min EPS beat(2)-471.19%
Max EPS beat(2)-73.94%
EPS beat(4)2
Avg EPS beat(4)-133.54%
Min EPS beat(4)-471.19%
Max EPS beat(4)8.51%
EPS beat(8)4
Avg EPS beat(8)-64.18%
EPS beat(12)7
Avg EPS beat(12)-42.07%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.55%
EPS NY rev (1m)-2.27%
EPS NY rev (3m)0.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.76
P/tB 1.76
EV/EBITDA N/A
EPS(TTM)-2.54
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.91%
ROE -29.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.37
Quick Ratio 26.37
Altman-Z 25.62
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)802.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.88%
EPS Next Y82.11%
EPS Next 2Y33.42%
EPS Next 3Y21.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.88%
OCF growth 3YN/A
OCF growth 5YN/A